tbuckley/cabot-search huggingface dataset:
PWE-136 Bowel Cancer Screening Non Responders: What Can Be Done to Increase Uptake in Men From Lower Socioeconomic Groups?
Authors: J Scott, P Elton, G Lipscomb, S Paynter, J Scott, N Hill
Journal: Gut (2016)

<h3>Introduction</h3> In the 2006 UK Bowel Cancer Screening Pilot, uptake levels were around 60%.<sup>1</sup> As of 2014, in Bolton, the uptake rate amongst men in the lowest deprivation quintiles was less than 50%.<sup>2</sup> This study aims to aims to discover the factors that influence Bowel Cancer Screening Non-Responders to not complete their kit; and to explore interventions to increase uptake in this population. <h3>Methods</h3> Between Sept 2012 and Sept 2013, 131 male BCS non-responders were exposed to incremental GP endorsement interventions of increasing intensity (letter, telephone call and the offer of a face to face interview). 10 non-responders were resistant to both letters and telephone calls, but consented to an interview. The interviews were semi-structured, and explored BCS attitudinal barriers and “Cues to Action” found in a review of the current literature. Analysis was performed using an inductive, grounded theory approach.<sup>3</sup> <h3>Results</h3> Interview analysis yielded 32 attitudinal and interventional themes. Common attitudinal themes included “the Poo Taboo”, “Masculinity” and “the NHS Disconnect”. Most participants felt embarrassed to talk about or handle their faeces (the Poo Taboo). Some felt that screening tests, particularly invasive tests, weren’t “manly” (Masculinity). A few declined the test, because they distrusted the local hospital or the NHS in general (the NHS Disconnect). Health literacy was low in this group, the majority knew very little about Bowel Cancer and Bowel Cancer Screening. Improving knowledge and health education were thought to be important interventional “Cues to Action”. <h3>Conclusion</h3> Bowel Cancer Screening Non-Respondence is a complex and multifactorial problem with no “silver bullet” solution. The subject of Bowels and Bowel Cancer Screening requires further normalisation. Strategies such as endorsement from Friends and Family; and GP group educational events were thought to be important tools for improving BCS perceptions, behaviour and ultimately response. <h3>References</h3> 1 Bowel Cancer Screening Pilot. http://www.cancerscreening.nhs.uk/bowel/pilot-2nd-round-evaluation.pdf 2 Bolton Health Matters. http://www.boltonshealthmatters.org/sites/default/files/PHIT-Report-10-Bowel-Cancer-Screening-in-Bolton.pdf 3 Crabtree B, Miller W, eds. <i>Doing qualitative research</i>. 2nd ed. Newbury Park, Calif: Sage; 1999. <h3>Disclosure of Interest</h3> None Declared
Mammogram Quality Assurance Program
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Review: Little evidence exists on the benefits and harms of screening for and treating gestational diabetes
Authors: Gavin Young
Journal: Annals of Internal Medicine (2008)

Source Citation Hillier TA, Vesco KK, Pedula KL, et al. Screening for gestational diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148:766-75. 18490689
Association News
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clear-Cell Hidradenoma and Hidradenocarcinoma
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Motivations studied and treatments devised in attempt to change rapists' behavior
Authors: D. Riesenberg
Journal: JAMA (1987)

NEWS ITEM: "In an opinion by Justice William Rehnquist, the [Supreme] court ruled 5-4 that persons accused of being 'sexuallly dangerous' in Illinois do not enjoy all the same constitutional protections as criminal defendants.... The state's chief interest in these cases is the treatment rather than the punishment of sex offenders."—<i>Chicago Tribune</i>, July 2,1986, p. 3. Should rapists receive treatment at taxpayers' expense? Although there may exist some negative reaction to the idea, it is gaining favor among experts in the field. Richard A. Maier, PhD, associate professor of psychology at Loyola University of Chicago, writes that, "since individuals convicted of violent sex crimes almost invariably return to society at one time or another, it seems that therapy should be attempted" (<i>Human Sexuality in Perspective. Chicago</i>, Nelson Hall Publishers, 1984, p 424). He notes that more is being learned about the motivations of rapists and that, increasingly, there are
Anesthesiology, Philadelphia
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROBLEM OF MEDICAL PATENTS
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 18004: The Next Generation of Stretchable Sensors for Intravascular Electrochemical Impedance Spectroscopy of Varying Levels of Lipid Burden and Atherosclerosis
Authors: Rene R Packard, XiaoXiao Zhang, Yuan Luo, Teng Ma, Nelson Jen, Jianguo Ma, Linda L Demer, Qifa Zhou, Rongsong Li, Yu-Chong Tai, Tzung K Hsiai
Journal: Circulation (2015)

Introduction: Atherosclerosis, a chronic inflammatory arterial disease, persists as the leading cause of acute coronary events or stroke in developed countries. Developing a reliable, reproducible, safe and simple strategy to detect lipid-rich, metabolically active, and mechanically unstable plaques remains an unmet bioengineering challenge. It is recognized that oxidized low-density lipoprotein (oxLDL) and macrophages produce changes in the electrochemical properties of vessel walls that can be measured by electrochemical impedance spectroscopy (EIS). Hypothesis: We tested the hypothesis that a new, 2-point intravascular micro-electrode configuration enables flexible frequency-dependent EIS characterization of lipid-rich lesions. Methods: A simplified yet robust sensor design with higher differentiating capability, featuring individually addressable, flexible round electrodes (Æ = 240 μm), was developed and microfabricated for intravascular EIS investigation. We documented in vivo deployment of stretchable EIS sensors for endoluminal interrogation and impedimetric investigation at multiple levels of the aortic tree characterized by differing stages of atherosclerotic disease in a New Zealand White rabbit model, compared EIS values in vivo and ex vivo, confirmed endoluminal atherosclerotic lesions by intravascular ultrasound, histology and immunohistochemistry, and obtained EIS profiles in epicardial fat tissue. Results: The frequency sweep revealed overlapping tissue resistivity from 1-10 kHz, but distinct capacitive property from 10-300 kHz, thereby providing complementary differentiation in both impedance (Ω) and phase (f) between healthy arteries and varying levels of atherosclerotic lesions. The EIS measurements revealed a significant increase in impedance in the presence of oxLDL-rich lesions from 5219 Ω in control to 5949 Ω in mild, 6988 Ω in moderate and 8351 Ω in severe plaque at 300 kHz (P &lt; 0.05, n = 5 controls, n = 3 atherosclerotic). The correlation between in vivo and ex vivo analyses using Spearman was r = 0.97 (P &lt; 0.0001, n = 8 aortic segments). Conclusion: We demonstrate a new, paired-electrode based EIS sensor for intravascular interrogation of lipid-laden lesions to complement diagnostic angiography.
Medical Journal of Australia, Sydney
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic and Therapeutic Technology Assessment (DATTA)
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE FICKER TYPHOID TEST.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells
Authors: P Casado, E H Wilkes, F Miraki-Moud, M M Hadi, A Rio-Machin, V Rajeeve, R Pike, S Iqbal, S Marfa, N Lea, S Best, J Gribben, J Fitzgibbon, P R Cutillas
Journal: Leukemia (2017)

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an effective treatment for hematologic malignancies.The most frequent cause of post-transplant mortality is disease relapse, the majority of the cases present recurrence of original disease from outgrowth of residual cells having
Chronic Fatigue
Authors: Jane Cuozzo
Journal: JAMA (1989)

<h3>To the Editor.—</h3> I am a patient suffering from chronic fatigue syndrome and I am appalled that it has been given such a trivial name. Here is a disease that totally disables most of its victims; a disease that causes balance disorders, resulting in some of us requiring wheelchairs, cognitive disorders that leave us unable to perform formerly simple mental tasks, and immune disorders that lay us open to multiple infections and to autoimmune problems. And all the medical profession can come up with to define this syndrome to the general population is "fatigue!" Let me be clear, the disabling weakness and exhaustion a patient with chronic fatigue syndrome experiences is so profound that<i>fatigue</i>is a euphemism at best, and more probably an insult. I have lain in bed for days, in pain because the muscles in my arms and legs were shaking from the strain of holding them
Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer
Authors: Marie Daugan, Lubka Roumenina, Rémi Noé, Florent Petitprez, Catherine Sautès-Fridman, Wolf H. Fridman
Journal: Cancer Research (2019)

Abstract Objective: The complement system has been considered for long as anti-tumoral effector in the context of monoclonal antibody therapy. Nevertheless, recent studies highlighted a pro-tumoral effect of complement, acting on angiogenesis, tumor cells proliferation and immunosuppression. The kidney is capable to produce a whole spectrum of complement components. Nevertheless, the role of complement activation for the progression of renal cancer remains poorly understood. In the present work we address the presence of complement components and their impact on the clinical outcome of patients with clear cell renal carcinoma (ccRCC). In addition, we evaluate the tumor growth of complement proteins-expressing tumor cell lines in complement-deficient mice. Methods: The production of complement proteins by RCC lines was measured by RT-qPCR and by western blot (WB). Their expression in the tumor tissue was evaluated by immunohistochemistry and multicolor staining by immunofluorescence (IF) on sections from paraffin embedded tumors. The capacity of RCC cells-produced proteins to activate complement was evaluated by ELISA and western blot. The presence of complement was evaluated by immunohistochemistry on tumor sections from 3 retrospective cohorts composed by primary ccRCC patients (over 300 cases total). Complement producing tumor cell lines were grafted in WT and classical complement pathway deficient mice and the tumor growth was followed. Results: We found that C1q is expressed in the ccRCC tumors by the infiltrating macrophages, having a particular phenotype. The remaining complement proteins are produced by the tumor cells. A dynamic interaction between the complement proteins produced by the tumor cells and the immune microenvironnement led to a local activation of complement revealed in vitro and in situ. The high level of C1q and complement activation correlated with a poor prognosis for patients. Moreover, the tumor growth was reduced in C1q-/- and C4-/- mice. Conclusion: Early steps of the classical complement pathway can be activated locally and are associated with a pro-tumoral effect in mice models and in patients with renal cancer. Keywords: renal cancer; C1q; classical pathway Citation Format: Marie Daugan, Lubka Roumenina, Rémi Noé, Florent Petitprez, Catherine Sautès-Fridman, Wolf H. Fridman. Intratumoral classical complement pathway promotes tumor growth in renal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2334.
Thyroid Hemiagenesis
Authors: O Sari, I Ciftçi, M Törü, B Erbaş
Journal: Clinical Nuclear Medicine (2000)

Thyroid hemiagenesis is a rare congenital anomaly in which one thyroid lobe fails to develop. Tc-99m pertechnetate scintigraphy and ultrasonography can be used to visualize this anomaly. The authors evaluated four cases with Tc-99m pertechnetate scintigraphy and ultrasonography and confirmed thyroid hemiagenesis. In one case, a Tc-99m MIBI scan excluded the suppresssion of the contralateral thyroid lobe. Tc-99m MIBI can be used to confirm the diagnosis of thyroid hemiagenesis.
Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
Authors: E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos, E Eleftherakis-Papaiakovou, K Tsionos, P Croucher, M A Dimopoulos
Journal: Leukemia (2008)
Endoscopic electrocoagulation of upper gastrointestinal hemorrhage
Authors: J. P. Papp
Journal: JAMA (1976)

Endoscopic electrocoagulation was performed on 40 occasions for 38 patients with bleeding gastrointestinal lesions. Cessation of bleeding was achieved in 95%. Fifteen gastric ulcers, 14 duodenal ulcers, six Mallory-Weiss tears, one gastric varix, one hemorrhagic antral gastritis, and one esophageal ulcer were successfully electrocoagulated. Three duodenal and three gastric ulcers rebled. One duodenal ulcer and one gastric ulcer were successfully reelectrocoagulated. Failure to stop bleeding by electrocoagulation occurred in one Mallory-Weiss tear and one duodenal ulcer. There was no morbidity nor mortality attributed to endoscopic electrocoagulation. A retrospective cost analysis showed that the cost of hospitalization was less in patients treated by electrocoagulation. Patients so treated were hospitalized for a shorter duration. (<i>JAMA</i>236:2076-2079, 1976)